39. The fusion protein as defined in any one of claims 1 to 30 for use in the treatment of neoplastic diseases in mammals, including humans.

~~40. A method of treating cancer diseases in mammal, including human, which comprises administration to a subject in a need thereof an anti-neoplastic effective amount of the fusion protein as defined in claims 1 to 30, or the pharmaceutical composition as defined in claims 37 or 38.~~

~~41. Peptide selected from the group consisting of a mutated variant of trichosantin of SEQ. No. 200, a mutated variant of catalytic subunit A of *Pseudomonas aeruginosa* toxin of SEQ. No. 201, a mutated variant of catalytic subunit A of *Pseudomonas aeruginosa* toxin of SEQ. No. 202, a mutated variant of catalytic subunit A of *Pseudomonas aeruginosa* toxin of SEQ. No. 204, a mutated variant of catalytic subunit A of *Pseudomonas aeruginosa* toxin of SEQ. No. 205, and a mutated variant of catalytic subunit A of *Pseudomonas aeruginosa* toxin of SEQ. No. 207.~~